Events

Übersicht

Kategorie: Invest in Basel region

Ort: Event Hall, Messeplatz | City Lounge, 4058 Basel

Gabriela Güntherodt

Ihre Kontaktperson

Gabriela Güntherodt

Head of International Markets & Business Affairs, Member of the Management Board

Nehmen Sie mit uns Kontakt auf
event Invest in Basel region
ROIVANT SCIENCES THIRD ANNUAL SYMPOSIUM «Innovation in Pharma Business Models»

28.05.2019

ROIVANT SCIENCES THIRD ANNUAL SYMPOSIUM «Innovation in Pharma Business Models»

 

The Event is already booked out. If you are interested in participation please write an email to andi.notexisting@nodomain.comdyla@roivant.notexisting@nodomain.comcom

 

The days of just selling the pill are over

Despite being the largest industry in the world and providing continuous medical breakthroughs, the healthcare industry is beginning to lag in terms of innovation. The industry is ripe for disruption across the value chain, be it in research or drug development, commercialization or partnering.

The Third Annual Roivant Symposium invites pharma and biotech leaders to openly share their views of the challenges, but more importantly, potential solutions through new business models in pharma and the wider healthcare space.

We are pleased to welcome our keynote speaker: Dr. James Sabry, Global Head of Partnering at Roche and Dr. Gillian Cannon, President of Alyvant. In addition, there will be a fireside chat with industry veteran and Chairman of Molecular Partners Bill Burns, as well as a panel discussion with other distinguished industry executives.

We look forward to a fascinating symposium

Please register here.

 

Program

17:00

Reception

17:30

Welcome
Vivek Ramaswamy, Founder and CEO, Roivant Sciences

17:40

Keynote Address
James Sabry, MD, PhD, Global Head Roche Partnering

18:00

Keynote Address
Gillian Cannon, PhD, President, Alyvant

18:15

Fireside Chat
Bill Burns, Chairman, Molecular Partners with
Sascha Bucher, Head of Roivant Basel Pharma & Global Transactions

18:30

Panel Discussion
Friedrich von Bohlen und Halbach, Founder and CEO, Molecular Health
Jeremy Sohn, Global Head of Digital Development and Business Development & Licensing, Novartis
Bo Rode Hansen, PhD, CEO,  Genevant
Moderator: Vivek Ramaswamy

 

Panelists

Vivek Ramaswamy, Founder and CEO, Roivant Sciences

Vivek Ramaswamy is the founder and CEO of Roivant Sciences, a global biopharmaceutical company focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D. He received his A.B. summa cum laude in Biology from Harvard and his J.D. from Yale Law School. He began his career as a successful biotech investor where he oversaw investments in numerous companies, including those that helped develop curative treatment regimens for hepatitis C virus.

James Sabry, MD, PhD, Global Head, Roche Pharma Partnering

Dr. James Sabry is the Global Head of Roche Pharma Partnering and a member of the enlarged Corporate Executive Committee. Prior to his current role, Dr. Sabry was the Global Head and Senior Vice President of Genentech Partnering. Before then, he served as President and CEO of Arete Therapeutics and co-founded Cytokinetics, where he served as President and CEO. Dr. Sabry holds a M.D. from Queen’s University in Kingston, Canada and a Ph.D. in Neuroscience from the University of California in San Francisco. He also completed a postdoctoral fellowship in biochemistry at Stanford University.

Gillian Cannon, PhD, President, Alyvant

Gillian Cannon is the President of Alyvant, a technology enabled pharmaceutical commercialization company with a mission to better connect patients to therapies that will benefit them. Dr. Cannon has over 25 years of experience in US, European and Global senior leadership positions at pharmaceutical companies including Merck, UCB and Otsuka.  She has expertise across a range of disciplines including Market Access, Sales, Marketing, Business Development and Strategic Planning. Gillian’s passion is leading senior management teams to successfully implement innovative industry initiatives that are driven by data and technology.

William Burns, Chairman, Molecular Partners

William “Bill” Burns is the Chairman of Molecular Partners. He worked for Roche in various positions for 28 years culminating in the position as CEO of Roche Pharmaceuticals and board member of Roche, Genentech and Chugai Pharmaceutical. He is also Chairman of Vestergaard and Vice-Chairman of Mesoblast. He was Senior Independent Director of Shire Pharmaceuticals. He is a Trustee and Governor of the Welcome Trust Ltd. and a Trustee of the Institute of Cancer Research, London.

Jeremy Sohn, Global Head of Digital Development and Business Development & Licensing, Novartis

Jeremy Sohn joined Novartis in 2015 as VP, Head of Digital Business Development & Licensing. In addition to serving in this role, Mr. Sohn was appointed Global Head of Commercial Digital Medicines and Global Head of Digital Development. He is a serial software entrepreneur with more than 20 years of experience founding and managing healthcare and technology companies. He is a Board Member and Advisor to a number of digital health companies, including Pear Therapeutics, Science 37, MintHealth, Neural Analytics, and COTA.

Friedrich von Bohlen und Halbach, PhD, CEO, Molecular Health

Dr. Friedrich von Bohlen und Halbach is founder and CEO of Molecular Health and Co-founder and Managing Partner of dievini Hopp BioTech. He holds a diploma in Biochemistry from the University of Zurich and a PhD in Neurobiology from the Swiss Federal Institute of Technology (ETH). He started his career at Fresenius, FAG Kugelfischer and WASAG Chemie. In 1997 he co-founded LION bioscience (now Expedeon), whose CEO he was for seven years. He is also chairman of Apogenix and Novaliq, as well as board member of AC Immune, CureVac, immatics biotechnologies, Heidelberg Pharma and member of the evaluation board of Wyss Translational Center, Zürich.

Bo Rode Hansen, PhD, CEO, Genevant

Dr. Bo Rode Hansen is the President and CEO of Genevant. Dr. Rode Hansen joined Genevant from Roche, where he served as Global Head of RNA Therapeutics and General Manager of the Roche Innovation Center Copenhagen. Prior to Roche, he was an Executive and Head of Drug Discovery & Alliance Management at Santaris Pharma A/S through the company’s acquisition by Roche in 2014. He is a pioneer in RNA therapeutics and has led multiple discovery programs translating into clinical candidates in the areas of oncology, infectious diseases, rare genetic-, neurological- and metabolic disorders.

Sascha Bucher, Head of Roivant Basel Pharma & Global Transactions

Sascha Bucher is Roivant’s Head of the Basel Office and Head of Global Transactions. Prior to joining Roivant, Sascha worked for Roche in numerous Business and Corporate Development functions including as Deputy Head of Global M&A where he was involved in 100+ transactions and negotiated and closed over 50 international deals. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager.

 

Gabriela Güntherodt

Ihre Kontaktperson

Gabriela Güntherodt

Head of International Markets & Business Affairs, Member of the Management Board

Nehmen Sie mit uns Kontakt auf
Cookies

BaselArea.swiss verwendet Cookies, um Ihnen den bestmöglichen Service zu gewähren. Wenn Sie auf der Seite weitersurfen, stimmen Sie der Cookie-Nutzung zu.

Ok